Brief: Paion: clinical development progress with remimazolam in China by partner Yichang Humanwell

PAION AG

21/12/2016 13:01

Dec 21 (Reuters) - Paion AG  PA8G.DE : 
    * Its Chinese remimazolam licensing partner Yichang 
Humanwell informed Paion that their second phase I study started 
in September 2016 has successfully completed recruitment 
    * Phase II study in procedural sedation in China will start 
shortly 
 
Source text for Eikon:  ID:nEQc9lqh5  
Further company coverage:  PA8G.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))